Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse

Inclusion Criteria: * Patients aged \> 18 * Histologically proven diagnosis of cancer of the ovary, the fallopian tube or peritoneum * Peritoneal and/or nodes and/or visceral metastases * Disease in progression under treatment or within 6 months after a first or second platinum-based line * A period of 3 weeks between last chemotherapy and inclusion * Measurable disease (Response Evaluation Criteria in Solid Tumors \[RECIST\] criteria) or cancer antigen (CA) 125 assessable disease (Gynecologic Cancer Intergroup \[GCIG\] criteria) * ECOG performance status \< 2 * Life expectancy of at least 12 weeks Exclusion Criteria: * Previously received weekly administration of paclitaxel chemotherapy * Involved in a trial within the last 30 days * Previously received a bone marrow autogreffe or irradiation of the abdomen within 5 years, due to intensive chemotherapy * Prior diagnosis of malignancy * History of ischemic cardiopathy, congestive heart failure (New York Heart Association \[NYHA\] \> 2), arrhythmia, hypertension, or significant valvulopathy * Pre-existing motor or sensory neurologic pathology or symptoms National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) grade \> 2 * Bone marrow, renal, or hepatic insufficiency * Severe active infection or occlusive or sub-occlusive disease * History of symptomatic brain metastases * Fertile women not using adequate contraceptive methods * Pregnant or breast feeding women * Hypersensitivity to compounds chemically related to paclitaxel, topotecan, or carboplatin